Regenera sees new applications for technology

Regenera (ASX:RGA) has picked up three new applications for ocular applications of its core product Visagen, a proprietary formulation of synthetic steroid triamcinolone acetonide.

According to CEO Dr William Ardrey, the acquisitions expand the coverage to include middle- and back-of-eye applications for Visagen, in addition to its use in surgical procedures and in combined drug and test kits.

The technology was acquired from US-based MINU, a company set up to commercialise patents developed by retinal and vitreous surgeon and scientist Dr Gholam Peyman. Peyman has recently joined Regenera's scientific team as medical research director.

Regenera will retain 75 per cent of future revenue streams from the acquired products.

Regenera announced yesterday that it had received ethics approval to commence Phase III clinical trials in Singapore for Visagen as a treatment for cystoid macular oedema.